Modification by Ubiquitin-Like Proteins: Significance in Apoptosis and Autophagy Pathways

Umar-Faruq Cajee, Rodney Hull and Monde Ntwasa *

School of Molecular & Cell Biology, Gatehouse 512, University of the Witwatersrand, Johannesburg, 2050, South Africa; E-Mails: umar.cajee@students.wits.ac.za (U.-F.C.); rodney.hull@students.wits.ac.za (R.H.)

* Author to whom correspondence should be addressed; E-Mail: monde.ntwasa@wits.ac.za; Tel.: +27-11-717-6354; Fax: +27-11-717-6351.

Received: 28 June 2012; in revised form: 11 September 2012 / Accepted: 13 September 2012 / Published: 19 September 2012

Abstract: Ubiquitin-like proteins (Ubls) confer diverse functions on their target proteins. The modified proteins are involved in various biological processes, including DNA replication, signal transduction, cell cycle control, embryogenesis, cytoskeletal regulation, metabolism, stress response, homeostasis and mRNA processing. Modifiers such as SUMO, ATG12, ISG15, FAT10, URM1, and UFM have been shown to modify proteins thus conferring functions related to programmed cell death, autophagy and regulation of the immune system. Putative modifiers such as Domain With No Name (DWNN) have been identified in recent times but not fully characterized. In this review, we focus on cellular processes involving human Ubls and their targets. We review current progress in targeting these modifiers for drug design strategies.

Keywords: ubiquitin-like; autophagy; apoptosis; immune response; DWNN; SNAMA; p53; Ubls; ubiquitin-proteasome; cancer

1. Introduction

Ubiquitin is a 76 amino acid protein, which is covalently attached to a lysine residue on a target molecule via a conserved carboxy-terminal glycine residue. Ubiquitin consists of two α-helices and five β-sheets in a βαββαβ arrangement. This structural fold (known as the ubiquitin globular β-grasp fold) is conserved in other proteins with no obvious sequence identity. These proteins are known as
ubiquitin-like (Ubl) modifiers and their identification has been increasing steadily over the years leading to the characterization of an entire superfamily [1]. Although Ubls do not share high sequence similarity with ubiquitin, all members of this superfamily are characterized by the same three-dimensional structure. Initially, proteins that are tagged by ubiquitination were thought to be marked for degradation via the proteasome pathway but other roles of ubiquitination have now been identified. Similarly, there are emerging Ubls that are involved in cellular processes other than degradation of proteins. The ubiquitin module or ubiquitin-like (Ubl) modifiers are ligated to target proteins by three enzymatic steps involving an activating enzyme (E1), a carrier or conjugating enzyme (E2) and a ligase (E3) [2]. Key residues on the modifier are required for these enzymatic reactions and are conserved in the ubiquitin superfamily. At the C-terminal end of ubiquitin and most Ubls there are conserved di-glycine residues. The C-terminal glycine is the key residue required for an isopeptide bond often with a lysine on the substrate protein. Ubiquitin has a set of highly conserved lysine residues namely; K^6, K^29, K^48 and K^63 all of which can either be mono- or polyubiquitinated. However, other amino acids such as cysteine and the α-NH2 groups of the N-terminal residues of polypeptides can also act as sites for modification [3–5].

Ubiquitin-mediated degradation of proteins is employed in many cellular processes and is implicated in biological phenomena such as immune response, development and programmed cell death [6]. Here, we review human Ubls. We focus on their impact on apoptosis, autophagy and on immune response. Furthermore, we explore the evolutionary history and function of a new modifier known as DWNN (Domain With No Name) whose functional significance is still unclear.

2. Ubiquitin-Like Modifiers as Independent Modules

There are nine phylogenetically distinct classes of Ubls including SUMO, NEDD8, ISG15, FUB1, FAT10, Atg8, Atg12, Urm1, and Ufm1. We report here the existence of a putative modifier known as DWNN whose characteristics resemble those of Ubls but with poorly defined biochemical and functional features (Table 1). Ubls are involved in cellular activities such as apoptosis, autophagy and signaling pathways that mediate biological processes like cell proliferation, immune response and development. Ubls share low primary sequence similarity but phylogenetic analysis shows some evolutionary relatedness and clustering albeit with weak nodes (Figure 1). The most common feature is their three-dimensional fold.

| Modifier   | Functions                                                                 | Accession     | Reference |
|------------|---------------------------------------------------------------------------|---------------|-----------|
| SUMO-1     | Nuclear transport, DNA replication and repair, mitosis and signal transduction | NP_001005781 | [7,8]     |
| SUMO-2     | Nuclear transport, DNA replication and repair, mitosis and signal transduction | NP_001005849 | [7]       |
| SUMO-3     | Nuclear transport, DNA replication and repair, mitosis and signal transduction | NP_008867    | [7]       |
| SUMO-4     | May modulate protein sub-cellular localization, stability or activity. Upon oxidative stress, conjugates to various stress defense proteins. Negative regulation of NF-kappa-B-dependent transcription | NP_001002255 | [9]       |
| Modifier | Functions | Accession | Reference |
|----------|-----------|-----------|-----------|
| NEDD8 | Cell cycle control and embryogenesis May be involved in the formation of aggresomes | NP_006147 | [7] |
| ISG15 | Modifies STAT1, SERPINA3G/PI2A, JAK1, MAPK3/ERK1, PLCG1, EIF2AK2/PKR, MX1/MxA, and RIG-I. May serve as a trans-acting binding factor directing the association of ligated target proteins to intermediate filaments. May also be involved in autocrine, paracrine and endocrine mechanisms. Displays antiviral activity | NP_005092 | [7,11] |
| FAT10 | Protein degradation. Regulates TNF-alpha-induced and LPS-mediated activation of innate immunity. Mediates mitotic non-disjunction and chromosome instability, in cancers. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner | NP_006389 | [1,12] |
| Ubi5 | Negatively regulates p53 | NP_001041706 | [13,14] |
| FAU | Translation Gene expression. Viral infectious cycle. Endocrine pancreas development. Cellular protein metabolic process | NP_001988 | [15] |
| Apg12/Atg12 | Autophagic vacuole assembly. Negative regulation of type I interferon production | NP_004698 | [16] |
| Putative Atg8 homologs | Increases cell-surface expression of kappa-type opioid receptor. Intra-Golgi traffic and transport. Intracellular transport of GABA (A) receptors. Apoptosis. Formation of autophagosomes. Formation of autophagosomes. Formation of autophagosomes | CAG38511 | |
| GABARAPL1 (Atg8L) | | NP_009266.7 | |
| GABARAPL2 (Atg8C) | | NP_00209.1 | |
| GABARAP (Atg8A) | | NP_07379.1 | |
| MAP1LC3C (Atg8E) | | NP_1159031 | |
| MAP1LC3A (Atg8F) | | NP_001078950 | |
| MAP1LC3B | | | |
| MAP1LC3B2 | | | |
| Ufm1, UFM1 | Protein Ufmylation | NP_057701 | [17] |
| DWNN | Unknown but may be involved in protein ubiquitination involved in ubiquitin-dependent protein catabolic process | 2C7H_A | [18] |
| URM | Unknown | CA113492 | [19] |

2.1. Small Ubiquitin-Related Modifier (SUMO)

The small ubiquitin-related modifier (SUMO) was discovered serendipitously in 1996 when it was observed to stably modify RanGAP1 [20,21]. SUMO shares only 18% amino acid identity with ubiquitin but their three-dimensional structures are virtually super-imposable. However, it differs from ubiquitin in overall charge topology indicating differences in the nature of their interacting partners [22]. It is now regarded as the most studied posttranslational modification by a Ubl and seems to affect the widest range of proteins when compared to other Ubls [23,24]. Four functional SUMO genes have been identified in the human genome generating four isoforms (SUMO-1/2/3 and 4). The SUMO-3 gene was derived from SUMO-2 and the encoded proteins share 86% sequence
identity. On the other hand, SUMO-1 shares only 44% sequence identity with SUMO-2 and -3 [25]. SUMO-4, encoded by a separate gene (SUMO-4), shares 85% identity with SUMO-2 and is expressed mainly in the kidney [9].

**Figure 1.** Phylogenetic analysis of ubiquitin-like modifiers and their protein sequence alignment. Protein sequences of the Ubl ubiquitin domains were initially aligned in MEGA 5, using the default ClustalW algorithm. The multiple sequence alignment was then analyzed and tweaked manually to ensure that important conserved residues (lysines, diglycine motif) were accurately aligned. The percentage similarity between each modifier and ubiquitin and the presence of a C-terminal di-glycine are marked on the phylogenetic tree (A). DWNN belongs to the group with proteins that have higher sequence identity with ubiquitin but it is the most distantly related in this group. The more distantly related UFM, Atg8 and Atg12 lack the conserved diglycine.
SUMO is conjugated via the C-terminal glycine to an ε-amino group on an internal lysine residue of the target protein. SUMOylation occurs via a series of reactions catalyzed by SUMO-specific enzymes using a stepwise mechanism that is analogous to modification by ubiquitin [21,23]. All the SUMO genes encode a precursor with a short peptide beyond the C-terminal diglycine, but SUMO cannot be transferred to the target protein unless the C-terminal glycine is exposed. This is accomplished by desumoylating enzymes such as sentrin specific proteases. These enzymes serve three purposes; to process precursor SUMO to mature forms, to deconjugate SUMOylated proteins and to depolymerize SUMO chains [26]. The SUMOylation pathway begins with the ATP-dependent activation of SUMO at the C-terminus by a heterodimeric SUMO activation enzyme consisting of SAEI (Aos1)/SAE2 (Uba2) [27]. The activated SUMO is then transferred through a transesterification reaction to Ubc9, the only known SUMO-conjugating enzyme (E2), forming a SUMO-Ubc9 thioester intermediate. The specificity for the substrate is determined by both Ubc9 and the E3 ligase. Although not mandatory, SUMOylation usually occurs within a consensus motif ψKxE (where ψ is a large hydrophobic residue and x any residue). In vitro SUMOylation can occur without the presence of E3 ligases, regardless of the consensus motif. In vivo, E3 ligases often enhance the modification by catalyzing the transfer of SUMO from Ubc9 to the target proteins. This consensus sequence is enough to promote SUMOylation in vitro but in vivo conjugation mainly occurs when the substrate protein is located in the nucleus [28]. An exception to this is Rac1, a Rho-like GTPase that induces the cytoskeletal rearrangements required for cell migration. Increased Rac1 activity requires the E3 ligase PIAS3 to SUMOylate Rac1, leading to higher levels of Rac1-GTP. This modification occurs in the cytoplasm and serves to increase cell migration and invasion [29].

As evidence shows in this section, SUMOylation confers several functions on target proteins namely; protein stability, subcellular localization, transcription activation, DNA repair, and other cellular events [21,23,30]. Modification of IκBα by SUMO prevents its degradation by ubiquitination thus maintaining a stable NF–κB in the cytoplasm. NF-κB, a transcription factor that is induced during cellular activities such as inflammatory response, is sequestered in the cytoplasm by IκB inhibitors in unstimulated cells. Signal induced activation of NF-κB is mediated by the ubiquitination and subsequent proteosomal degradation of IκBα. SUMO inhibits this degradation by modifying IκBα at K12 and K22; the same sites required for ubiquitination [31,32]. Thus SUMO regulates this signaling pathway by competing with ubiquitin thereby antagonizing the degradation of NF-κB.

SUMOylation is involved in both negative and positive regulation of gene transcription. SUMO does not bind directly to DNA but appears to influence transcriptional activity indirectly by interacting with transcription factors as mutations in SUMO modification sites on transcription factors such as Elk-1, Sp-3, C/EBPs and c-myb result in repression [24]. Regulation of transcription repression by SUMO is illustrated by SUMOylated histone deacetylases (HDACs). Point mutations on SUMOylation sites of class I and II HDACs cause defects in their ability to repress transcription. SUMOylation of these proteins is coupled to nuclear localization and requires the presence of an intact nuclear localization signal. Furthermore, it occurs at the nuclear pore complex and is catalyzed by a SUMO E3 ligase, the nuclear pore complex (NPC) RanBP2 protein [33].

In the Wnt signaling pathway SUMO is reported to have a positive effect on gene transcription. A point mutation in TCF (Tcf-4K297R) results in reduced activation by β-catenin and the SUMO E3 ligase PIASy compared to wild type Tcf-4. In other experiments, it was shown that the knock down
of the desumoylation enzyme, Axam increases SUMOylation and activation of Tcf-4 [34,35]. SUMOylation also converts the heat shock transcription factor, HSF1 into a DNA-binding form thus promoting transcription in response to stress such as elevated temperature [36].

SUMOylation affects post-replication DNA repair by influencing several molecules involved in the cell cycle or in replication. The p53 family of proteins (including p63 and p73) which are regarded as guardians of the genome are regulated by SUMOylation at their C-termini. The prototypical tumor suppressor protein p53 is known to be constitutively and negatively regulated by the ubiquitin ligase Mouse double mutant 2 (Mdm2) in normal cells. SUMOylation of p53, usually at K389, increases after its DNA damage induced stabilization [37]. Moreover, over-expression of SUMO-1 activates wild type p53 transcriptional activity but not that of the mutant p53K386R. This points to the involvement of SUMOylation in p53 DNA damage repair activities. It is noteworthy that ubiquitin and SUMO-1 do not compete for the same site on p53 in this instance [38]. The proliferating cell nuclear antigen (PCNA), a DNA-polymerase sliding clamp involved in replication and DNA repair, is conjugated to SUMO-1 by the SUMO conjugating enzyme Ubc9 after increased DNA damage. Interestingly, PCNA is SUMOylated and ubiquitinated on the same residue; (K164) [39].

In an extensive review, [40] discuss a wide range of prominent nuclear proteins that are modified by SUMO and note that all the major DNA-repair pathways are regulated by either ubiquitination, SUMOylation or both.

Finally, the last to be identified SUMO-4 appears to have a different functional mechanism compared to the others. In its mature form it has a proline residue at the C-terminus instead of the conserved glycine. This introduces conformational constraints limiting the ability of SUMO to be part of an H-bond network required in covalent interactions. SUMO-4 was predicted therefore to participate in non-covalent interactions and was shown to function in conjugating DNA repair proteins functioning in base excision repair [41]. In a separate study a M55V polymorphism in SUMO-4 was found to be associated with type 1 diabetes mellitus [9]. This may be consistent with the high expression of SUMO-4 in kidneys.

2.2. Neural Precursor Cell-Expressed Developmentally Down-Regulated (NEDD8)

The neural precursor cell-expressed developmentally down-regulated (NEDD8) is another highly studied ubiquitin-like protein and shares the highest sequence identity (approximately 60%) with ubiquitin [42]. NEDD8 modifies target proteins in a manner analogous to ubiquitin—in a series of reactions involving NEDD8 activating E1-like enzyme (APP-BP1/Uba3), NEDD8-specific E2 enzymes (Ube2F or Ubc12) and the really interesting new gene (RING)-finger protein ROC1 (NEDD8 E3 ligase). The nature of chain formation by NEDD8 has been investigated in vitro and found to have subtle differences to polyubiquitination. NEDD8 chains can be linked via the catalytic cysteine residue of Ubc12 (E2) forming a thioester bond in the absence of ROC1 (E3) activity. Indeed ROC1 ligase E3-inactive mutants enhance poly-neddylation and a RING finger inhibitor enhances poly-neddylation of Ubc12 [43]. In yeast, NEDD8 was found to be ligated to members of the Cullin/Cdc53 family thus functioning as part of the Skp1-Cdc53/Cul-1-F-box (SCF) complex [44]. All human Cul family proteins were shown to be targets of Neddylation and NEDD8 and Cul family protein tissue distribution coincides [45]. Neddylation therefore is important for a variety of biological...
processes and has implications for pathological conditions especially those related to proliferation of cells such as cancer.

Neddylation is required for the regulation of the multifunctional transcription factor—NF-κB, which is crucial in immune response and apoptotic pathways. In the NF-κB pathway scenario, NEDD8 promotes the function of the SCF E3 ligase by recruiting the ubiquitin conjugating enzyme E2 thus augmenting the function of the SCF complex as a E3 ligase for ubiquitination of IκBα [46]. Cullins serve as scaffold proteins for the assembly of multicomponent Cullin RING E3 ligases (CRLs). These CRLs participate in the ubiquitination and proteasomal degradation of target proteins. In addition to this, there is a large number of substrate recognition subunits that assemble onto the Cullin scaffold allowing for a wide variety of targets to be ubiquitinated [47,48]. CRLs target numerous substrates and, therefore, regulate a wide range of biological processes. These include cell growth, development, signal transduction, transcriptional control, genomic integrity and tumor suppression [49]. Mutations in CUL7 and CUL4B genes are linked to hereditary human diseases [48]. Cullin4 mutant mice exhibit increased resistance to UV induced carcinogenesis as a result of an impairment in the nucleotide excision repair pathway underlining the important role played by Cullins in DNA damage repair. This is accomplished through the selective degradation of damage sensors such as the DDB2 (damage-specific DNA-binding protein) and XPC (Xeroderma pigmentosum) and checkpoint effectors p21/CIP1/WAF1 [50]. Nearly all members of the Cullin family require the mononeddylation of a conserved lysine residue to stimulate the ubiquitin activity of the CRLs [48]. Neddylation of Cullin3 leads to the negative regulation of the hedgehog pathway, which has been implicated in cancer [51]. Evidence obtained from deletion studies using C. elegans, D. melanogaster and M. musculus reveal that Cullins affect many physiological processes to do with cell proliferation and survival. Consequently, deletion of genes that encode Cullins has an impact on biological processes and phenomena like development and apoptosis [49].

In addition to Cullins, the most studied substrates for neddylation are other proteins involved in cell proliferation, viability and development. These include p53, EGFR, pVHL, ribosomal proteins and BRCA (breast cancer-associated protein) [52,53]. The identification of ribosomal proteins was conducted in a proteomics study revealing a subset of large and small ribosomal proteins that are neddylated. It was also shown that loss of neddylation causes protein instability [54].

NEDD8 is involved in the regulation of gene transcription by enhancing DNMT3b-dependent DNA methylation. It is well known that in cancer cells many promoters become aberrantly methylated. DNA methyltransferases such as DNMT3 interact with NEDD8 modified proteins (DNMT3b) and directly with NEDD8 (DNMT3a). DNMT3 is also known to interact with neddylated Cullins resulting in the formation of repressive chromatin marks [55].

Lastly, neddylation influences the IAP (inhibitor of apoptosis) pathway in both vertebrates and invertebrates. This was demonstrated by the fact that knocking down the expression of isopeptidase enzymes that remove the NEDD8 modification, leads to suppression of Drosophila Hid- and Reaper-induced apoptosis. Neddylation contributes to the regulation of apoptosis by controlling the ability of IAPs to mediate the conjugation of NEDD8 to effector caspases. Furthermore, downregulation of Deneddylase (DEN1), an enzyme that is responsible for the removal of NEDD8 from target proteins, was found to suppress apoptosis further supporting that neddylation prevents
apoptosis [56]. Overall, the pivotal role neddylation plays in replication and cell cycle events points to its importance in cell proliferation, death and survival.

2.3. Human HLA-F Adjacent Transcript 10 (FAT10)

FAT10 is an 18 kDa Ubl, which shares moderate sequence similarity with ubiquitin, (29% and 36% at the N- and C- termini respectively). It was first identified amongst genes in the HLA-F locus and found to be expressed in lymphoid cell lines [57]. Soon after that, FAT10 was shown to be constitutively expressed in lymphoblastoid cells and in dendritic cells and to be induced in certain other cells by pro-inflammatory stimuli [58]. These two studies reveal the unique features of this modification, namely that it is found in vertebrates only and is expressed by specific stimuli in a tissue-specific manner. Also known as diubiquitin (owing to the two ubiquitin-like domains in tandem, head-to-tail) this Ubl relies on its C-terminal diglycine motif for modification of its substrates [1]. Both domains contain a lysine residue mapped to ubiquitin K48 which could serve as the site for FATylation [59]. FAT10 modification is mediated through the Uba6 (E1) and USE1 (E2) enzymes, which are specific to both FAT10 and ubiquitin [60,61].

FAT10 has potential function in regulating the cell cycle, tumorigenesis, inhibition of cell proliferation and in survival. It also plays a significant role in immune response. For example, FAT10 expression is induced by interferon-γ and tissue necrosis factor α (TNFα) [62]. Deletion of mouse FAT10, which is highly similar to the human one, results in lymphocytes that are prone to spontaneous apoptotic death and sensitive to endotoxin exposure [63]. Furthermore, FAT10 appears to mediate the activation of NFκB, a key mediator of innate immunity [64]. FAT10 has been shown to change the conformation of p53, thereby stimulating its transcriptional activity [65]. It is also implicated in the regulation of mitosis and chromosomal stability [66] and in caspase-dependent apoptosis [67]. Indeed, increased FAT10 gene expression has been observed in several oncogenic conditions including liver, gynecological and gastrointestinal cancers [59,67]. Notably, FAT10 is overexpressed when cancer occurs in a pro-inflammatory environment consisting of interferon-γ and tumor necrosis factor α-cytokines that synergistically upregulate the expression of this modifier [62].

FAT10 has a short half-life due to rapid degradation by the proteasome in a process that seems to be dependent on polyubiquitination, as degradation is inhibited in cells that express a mutant form of ubiquitin that lacks the conserved lysine residue required for polyubiquitination [68].

It has been found that in Hep3B, a human cell line derived from the liver, FAT10 is repressed when the cells express p53. Furthermore, p53 was also shown to bind to FAT10 promoter in in vivo studies [69]. FAT10 is therefore transcriptionally controlled by p53.

2.4. Interferon Stimulated Gene 15 (ISG15)

The ubiquitin-like ISG15 protein is a 17 kDa protein that is understood to be primarily an anti-viral response gene whose expression is induced by type I IFN (interferon), LPS (lipopolysaccharide), and poly(I:C), a synthetic inosine polymer that resembles the RNA of infectious viruses [70]. ISG15 is one of the various proteins induced by interferon (IFN)α/β and also amongst the first Ubls identified [71]. Upon discovery, ISG15 was found to be under the control of an upstream enhancer element that was IFN inducible [72]. This enhancer element located in the ISG15 promoter includes a putative
p53-responsive element. The induction of ISG15 by p53 was demonstrated in HeLa cells using a temperature sensitive mutant of p53. Transfected cells grown at 37 °C expressed a mutant form of p53 that was unable to induce ISG15 expression. When the temperature was lowered to 32 °C allowing p53 to resume the wild type form, ISG15 was induced within 6 h. Interestingly, dsRNA induced ISG15 in a p53-dependent manner whereas induction by virus infection was not dependent on p53 suggesting that dsRNA and p53 may have overlapping profiles of induced genes and employed different signaling pathways [73].

ISG15 has so far been found in higher eukaryotes only and is absent from insects implying that ISG15 is restricted to animals that have evolved an IFN signaling pathway [74]. Like ubiquitination, conjugation of substrate proteins by ISG15 (ISGylation) follows a three-step enzymatic cascade using an E1 activating enzyme (Ube1L), an E2 conjugating enzyme (UbcH6 and UbcH8), and several E3 ligases such as EFP (estrogen-responsive finger protein) and the HECT (homologous to E6-AP C-terminus)-type E3 ligase Herc5. Both E3 ligases are inducible by interferon [75,76]. Ube1L is a 112 kDa protein that is a specific ISG15-activating E1 enzyme. In addition, Ube1L has a C-terminal ubiquitin fold domain that is required for the transfer of ISG15 [77]. UbcH8 and UbcH6 are ISG15-conjugating E2 enzymes that are induced by type I IFNs and viral infection. However, UbcH8 was originally identified as an ubiquitin-conjugating E2 enzyme interacting with other ubiquitin E3 ligases, such as Parkin and Dorfin [77]. Herc5 is the predominant ligase for ISG15, as knock down of the encoding gene by RNA interference abolishes most IFN-induced ISGylation [78].

ISG15 has characteristics pointing to its vital role in the innate immune response to viral infections. Over 150 to 300 proteins have been identified as ISGylation targets and found to be newly synthesized proteins associated with polyribosomes [11,79]. Mass spectrometric identification of ISGylated proteins also revealed a set of IFN-induced and Jak/STAT pathway signaling molecules [74]. EFP is a member of the TRIM family of proteins which are implicated in antiviral responses [80]. Moreover, the expression of EFP in human culture cells was found to be stimulated by the binding of STAT1 to an interferon–stimulated response element (ISRE) in an interferon dependent manner [81].

The involvement of ISGylation in antiviral response is now well documented and its impact on specific viruses has been recorded. The over-expression of ISG15 in cell culture suppresses the replication of a broad range of viruses including Sindbis virus [82,83], HIV [84], Ebola VP40 [85] and Herpes [83]. In addition to this, the influenza NS1B protein antagonizes ISGylation [86] while at the same time it is a target for Herc5-dependent ISGylation [87]. Infection by NS1A inhibits host cell pre-mRNA processing, resulting in the inhibition of IFN function but ISGylation of NS1A impairs the ability of the virus to replicate [78]. Consequently viruses have evolved specific proteins that function to deconjugate ISG15 from target viral proteins and thereby evading the anti-viral response [74].

The human pathogen Crimean Congo hemorrhagic fever virus (CCHFV) evades the innate immune system by de-ubiquitinating components of the antiviral signaling pathways. Some of the proteins in this pathway rely on the modification of proteins with the Ubl modifier, ISG15. The virus can shut down this pathway through the viral encoded ovarian tumor (vOTU) family deubiquitinase, which is able to target ISG15 modifications. Despite differences between ISGylation and ubiquitination enzyme kinetics, vOTU family deubiquitinase cleaves ubiquitin and ISG15 with similar kinetics. This is most likely due to the similarities in the C-terminal ubiquitin-like fold of ISG15 (ISG15-C). However, there is a second unique binding site for vOTU in ISG15-C [88].
The viral response via the JNK pathway is also regulated by ISG15. When ISGylation is extended by the deletion of the ISG15-specific protease UBP43, IFN signaling results in extended STAT1 activation and INF-mediated gene activation [89]. IFN stimulates the binding of MAPKs to filamin B, stimulating JNK activation and resulting in JNK-mediated apoptosis. ISGylation of filamin B prevents the binding of these MAPKs and prevents JNK mediated apoptosis [90].

2.5. Autophagy-Related (ATG) Genes

Autophagy is a process of self-degradation whereby cytoplasmic components are sequestered within double-membrane autophagosomes and subsequently delivered to the lysosome where they are broken down into individual amino acids. Autophagy is important in diseases such as neurodegeneration and cancer [91]. Two Atg proteins, Atg8 and Atg12 have been identified as Ubls that possess a ubiquitin-like fold and adopt a ubiquitin-like mechanism to modify substrate proteins [92].

Atg8 is a lipid-conjugated ubiquitin-like protein. Atg activation is catalyzed by Atg7 (E1) forming a thioester bond between its own C507 and the C-terminal glycine of Atg8. Atg8 is then transferred to the E2 enzyme Atg3. Finally, the Atg12-Atg5-Atg16 complex acts as an E3 ligase transferring Atg8 to phosphatidylethanolamine via a C-terminal glycine [93]. The transfer of Atg8 to lipids is initiated by the removal of a carboxy-terminal arginine residue by the cysteine protease Atg4 revealing a carboxy-terminal glycine [94].

The enzyme cascade responsible for the transfer of Atg12 to its target molecules involves other Atg proteins Atg5, Atg7 and Atg10. Atg7 functions as the E1 enzyme and Atg10 as an E2 [1,95]. Atg7 shows little sequence similarity to other E1 enzymes, however, it shares a conserved ATP binding domain: a metal-binding motif and an active-site cysteine residue with other E1 enzymes including Uba2, Uba3, Uba4 and Uba5. The ATP-binding domain is essential for the formation of the Atg12-Atg5 conjugate [16]. The E2 enzyme Atg10 forms a thioester bond with activated Atg12 on C133. Apg10p, a protein conjugating enzyme in yeast, shows no significant similarity to other E2 enzymes [96]. Atg12 is then transferred to Atg5. There is no identified typical E3 enzyme involved in this transfer. The Atg12-Atg5 complex interacts further with a small coiled-coil protein, Atg16, and Atg12-Atg5-Atg16 forms a multimeric complex through the homo-oligomerization of Atg16 [97]. This multimeric complex is found on the outer side of the autophagosomal membrane and acts as an E3 ligase in the transfer of Atg8 [77]. Atg3 has also been identified as a substrate for Atg12. Atg3 is an E2 enzyme and performs this function by autocatalytically transferring Atg12 to itself. The Atg12-Atg3 complex formation limits the increase in mitochondrial mass preventing mitochondrial pathways from rescuing dying cells and, thereby, promoting apoptosis [98]. Although the complex dissociates once the assembly of the phagosome is complete, no specific Atg12 hydrolase has been identified [77]. The mechanism by which this process occurs is therefore not clear.

2.6. Ubiquitin-Related Modifier 1 (Urm1)

Urm1, first identified in yeast together with its E1 enzyme Uba4, was found to have the unique properties of affinity for prokaryotic enzyme systems and resemblance to prokaryotic proteins involved in sulfur transfer [99]. It was, however, found to have a β-grasp structure similar to
ubiquitin [100]. Urm1 is conserved across all eukaryotes and shares structural similarities with evolutionarily ancient sulfur carrier proteins. It is an unusual ubiquitin-like modifier as it contains a thiocarboxylate group at the C-terminus and is involved in the transfer of a sulfur group and modification of certain tRNA species [77]. It has been found that reduction of cellular Urm1 levels causes severe cytokinesis defects in HeLa cells, resulting in the accumulation of enlarged multinucleated cells [19]. The unique features of this modification may represent some evidence for the ubiquitin system in prokaryotes.

2.7. Ubiquitin-Fold Modifier 1 (Ufm1)

Ufm1 is a 9.1 kDa protein, sharing 16% sequence identity with ubiquitin [101]. Unlike other Ubls Ufm has only a single glycine at its C-terminus [101]. The newly synthesized protein is cleaved by UfSP1/2 to expose this glycine, forming a mature Ufm1 [101]. Activation by the E1 Uba5 is followed by transfer to Ufc1 (E2) [102]. Recently, a Ufm1 E3 ligase and substrate have been identified and named Ufl1 and C20orf116, respectively [102]. This protein conjugate is then cleaved by the UfSPs mentioned earlier. Although Ufm itself is not yet fully understood regarding function, the conjugation was found to be abundant in the liver and lungs of Ufm1-transgenic mice [102]. The E1, Uba5, is essential for erythroid differentiation in mice, and deficiencies cause death from anemia, as a result of impaired differentiation as well as an increase in apoptosis of megakaryocyte and erythroid precursors [103]. This is the newest form of modification, and information about its biological significance is still patchy.

2.8. Domain with no Name (DWNN)

The recently discovered putative ubiquitin-like modifier DWNN shares about 28% identity with ubiquitin, but together they possess an almost superimposable three-dimensional structure. DWNN is a 76 residue protein found in vertebrates as an N-terminal domain of the Retinoblastoma Binding Protein 6 (RBBP6) family (also known as mouse proliferation potential proteins (P2P-R) or p53-associated cellular protein-testes derived (PACT)) or as an independent module encoded by its own transcript. It lacks the conserved K\(^{48}\) and K\(^{63}\), but in most cases K\(^{6}\) and K\(^{29}\) are conserved [18,104,105]. The residues are not conserved in protists and worms. Although the three-dimensional structure of DWNN is similar to that of ubiquitin the charge topologies are significantly different (Figure 2). Ubiquitin has a much more prominent negative surface compared to DWNN whose surface is largely positively charged. These features suggest that the two domains have different interacting partners. This domain is not found in prokaryotes but is present in all eukaryotes. Similarly, the RBBP6 protein family is found in eukaryotes only and appears to exist as a single copy gene with no transcript variants in plants and in invertebrates.
**Figure 2.** Comparison of charge topologies of DWNN and ubiquitin viewed in SPDBviewer. The positive charges are shown in blue while the negative charge is shown in red. Ubiquitin shows an equal charge distribution while DWNN shows a much higher positive charge. This implies that ubiquitin will probably be able to associate with a wider range of proteins due to it having negative and positive areas. Note the diglycine gives a negative charge in both molecules allowing them to associate with the positively charged lysine during modification.

In plants, invertebrates and vertebrates RBBP6 proteins have a multi-domain arrangement with combinations of the p53- and Rb- binding, and SR domains in addition to the core ubiquitin-like domain that is linked to a zinc knuckle and RING finger (Figure 3) [104,105]. With the exception of vertebrate orthologues, DWNN lacks the characteristic C-terminal diglycine motif required for conjugation of ubiquitin and Ubls to substrates. The significance of this is not yet clear. These proteins are associated with cell- and tissue- specific cell proliferation, apoptosis and mRNA splicing. In some experiments using mice RBBP6 proteins have been shown to enhance the activity of Mdm2 (mouse double mutant). Interestingly, Rbhp6 and mdm2 mice also have a similar phenotype. The loss of RBBP6 has an embryonic lethal phenotype while double mutants of Rbhp6 and p53 develop better [106]. This phenotype is similar to that of mdm2−/−/p53−/− [107]. Taken together, these observations point to a close association between the function of Mdm2 and RBBP6. Although DWNN was identified earlier than UFM1, very little is known about the enzymology of conjugation. Indeed it is not known whether this domain can be conjugated to other proteins in the ubiquitin-like fashion. The existence of the mammalian DWNN domain as an independent module, however, points to this possibility.
**Figure 3.** Phylogenetic analysis of proteins with DWNN domains. Full RBBP6 orthologous protein sequences were aligned in MEGA 5, using the default ClustalW algorithm. The multiple sequence alignment was then analyzed and tweaked manually to ensure important conserved residues (lysines, di-glycine motif) were accurately aligned.
3. Proteins with an Ubiquitin Domain

There is a set of cellular multi-domain proteins with Ubls that are often arranged together with the RING-finger motif. These proteins are encoded by a single transcript and consist of the ubiquitin-like domain usually at the N-terminus and a RING-finger motif somewhere along the length of the protein. In this section we discuss the structural organization and function of the currently characterized proteins (Table 2).

Table 2. Proteins with ubiquitin-like domains.

| Protein  | Function                                                                 | Accession Number  | Reference |
|----------|--------------------------------------------------------------------------|-------------------|-----------|
| Parkin   | Acts as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Regulates neuron death. Limits the production of reactive oxygen species. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene | NP_004553        | [108]     |
| UHRF1    | Important for G1/S transition. May be involved in DNA repair and chromosomal stability | NP_037414.3      | [109]     |
| UHRF2    | Important for G1/S transition. May be involved in DNA repair and chromosomal stability | CAI13295.1       | [109]     |
| RAD23    | Involved in nucleotide excision repair                                   | NP_005044.1      | [110]     |
| BAG1     | Regulation of proteasomal and lysosomal protein                          | NP_001165886     | [111]     |
| BAT3     | Involved in DNA damage-induced apoptosis. Immuno-proteasomes to generate antigenic peptides via targeted degradation. Post-translational delivery of tail-anchored (TA) membrane proteins to the endoplasmic reticulum membrane | BAB63390.1       | [112]     |
| DDI1     | Protein degradation                                                      | NP_001001711.1   | [113]     |
| DDI2     | Protein degradation                                                      | NP_115717.3      | [113]     |
| OASL     | Immune response cytokine-mediated signaling pathway interferon-gamma-mediated signaling pathway type I interferon-mediated signaling pathway | NP_003724        | [114]     |
| HERPUD1  | Cellular calcium ion homeostasis. Response to unfolded protein. Endoplasmic reticulum unfolded protein response. Negative regulation of caspase activity | NP_001010989     | [115]     |
| RBBP6    | Unknown but may be involved in protein ubiquitination involved in ubiquitin-dependent protein catabolic process | NP_008841.2      | [104]     |
| UBQLN1   | Response to Hypoxia. Apoptosis. Regulation of ubiquitination             | NP_038466        | [116]     |
3.1. Homocysteine-Inducible, Endoplasmic Reticulum Stress-Inducible, Ubiquitin-Like Domain Member 1 (Herpud1)

Herpud is a 55 kDa protein first identified as playing a role in endoplasmic reticulum (ER) stress response during hyperhomocysteinemia [115]. The N-terminus of Herpud has a ubiquitin-like domain which is likely to facilitate Herpud degradation by the ubiquitin proteasome system [115,117]. Herp is localized in the ER of neurons and other tissues and may act in ER-folding and in ER-associated degradation (ERAD) of proteins [118]. So far Herpud function is associated with neuroprotection through mitochondrial and Ca\(^{2+}\) homeostasis in the brain [119] and prevention of apoptosis in response to stress [119,120]. Herpud may also decrease protein load and increase the capacity the ER to fold [120].

3.2. Parkin

The human Parkin gene was found to be responsible for the pathogenesis of autosomal recessive juvenile parkinsonism. It is a 51.6 kDa protein with a ubiquitin-like domain at the N-terminus and two RING finger motifs separated by an in-between-RING-finger (IBR) motif at the C-terminus [121,122]. It has been demonstrated that Parkin functions as an E3 ligase and that it interacts with a number of proteins including E2 enzymes and putative substrates [123,124]. A number of these Parkin substrates are proteins that are linked to neurodegenerative disorders. Furthermore, the Drosophila homolog of the parkin gene is an E3 ligase that interacts with Ubc-H8 and it appears to act via the RING-finger motif. Parkin also appears to act in a pathway of p53-mediated apoptosis [125].

3.3. Retinoblastoma Binding Protein 6 (RBBP6)

The Retinoblastoma Binding Protein 6 (RBBP6) proteins also known as Proliferation Potential related (P2P-R) or the p53-associated cellular protein-testes derived (PACT) in the mouse [126,127] or SNAMA in Drosophila are found in all eukaryotic organisms but not in prokaryotes. They are characterized by the DWNN domain at the N-terminus and an associated zinc knuckle and RING-finger motif. Orthologous forms have different combinations of domains and motifs including the p53 binding domain, RB-binding domain, the SR motif and others [18,104,105,126,128]. RBBP6 proteins are found as single isoforms in invertebrates and in the plant kingdom but various isoforms are predicted in vertebrates (see Figure 3). Null mutants of mouse PACT are not viable, but can be rescued by simultaneously knocking out p53 [106]. An alternatively spliced version of PACT is involved in cell cycle arrest and is responsible for camptothecin-induced apoptosis [128]. PACT itself most likely regulates p53 activity by interfering with the ability of p53 to bind DNA [127]. PACT also interacts with Mdm2, and enhances Mdm2-mediated ubiquitination and degradation of p53 suggesting that it is a negative regulator of p53 [106].

The Drosophila orthologue was found to be important for apoptosis and to play an active role in nucleic acid metabolism during embryonic development. SNAMA (mini-me locus) is expressed throughout development with higher levels during early embryonic development compared to later stages [18,104,105]. The RBBP6 proteins have not been shown to mediate E3 ligase activity
even though they have the hallmarks of E3 ligase such as the RING-finger motif and the ubiquitin-like domain.

3.4. Ubiquilin

Ubiquilin is a protein consisting of three domains; a ubiquitin like domain, a ubiquitin associated domain and a third domain that is highly conserved in several other large ubiquitin-like proteins. Ubiquilin expression was originally found in the testes [129].

Yeast two-hybrid assays identified ubiquilin as a protein that interacts with protein disulfide isomerase (PDI). Following cellular stress such as hypoxia both these proteins localize to the endoplasmic reticulum. Hypoxia causes the accumulation of immature proteins, which may eventually initiate cell death. Over-expression of ubiquilin leads to a decrease in hypoxia induced apoptosis. This protection is increased when PDI is over-expressed in conjunction with ubiquilin. As this only protected cells from hypoxia induced apoptosis it was deduced that ubiquilin selectively blocks ER stress induced apoptosis. Ubiquilin and PDI act by delaying the expression of DNA damage-inducible transcript 3 protein [130].

4. Potential for Therapeutic Intervention

The involvement of several ubiquitin-like modifiers in cancer pathogenesis was recently reviewed by [131]. Modification and de-modification by the Ubls and ubiquitin as well as poly- and mono-ubiquitination, alter the function of a number of proteins which show direct involvement in various cancer pathogeneses, including lymphomas, melanomas, lung, ovarian, prostrate and leukemia, among others. Specifically, SUMO activity in chromatin remodeling, through sumoylation of proteins, cofactors and transcription factors involved therein, directly influences transcriptional activity and regulates other signaling pathways. One such pathway is the Wnt pathway. When β-catenin is stimulated by the Wnt ligand it localizes to the nucleus to recruit chromatin remodeling complex and thereby activates transcription. Tumor metastasis is promoted by the expression of the KAI1 gene, which is usually repressed by a SUMO modified Reptin (involved in β-catenin chromatin remodeling complex). Exploiting this interaction by downregulating Ubc9 (a Sumo E2), or by over-expressing SENP1 (a desumoylating enzyme) inhibits metastasis by promoting KAI1 expression [131].

ISG15 conjugation may be similarly implicated in lung cancer and APL (acute promyelocytic leukemia). Ube1L and Ubp43 levels are affected by these cancers. After treatment aimed at these cancers (doses of all transretinoic acid), Ube1L mRNA is increased. However, detailed effects of ISG15 and its enzymes in tumor suppression are yet to be explained [131].

The innate immune system plays a role in tumor suppression through the activation of IFN. In this way ISG15 plays a role in tumor suppression. Camptothecin and other chemotherapies can induce ISG15 expression in a JAK/STAT independent method. This implies a separate pathway to that used in an anti-viral response. Additionally camptothecin induced ISG15 activation results in a unique set of proteins being ISGylated [132]. When recombinant human IFN was added to colorectal cancer xenografts in combination with camptothecin, the result was an increase in the antiproliferative effects of camptothecin [133].
5. The Ubiquitin and Ubiquitin-Like Protein System as a Drug Target

It is clear that the ubiquitin-proteasome system is implicated in a number of physiological processes. Primarily, it controls the level or rather turnover of proteins in eukaryotic cells thus playing a key regulatory role in signaling events. After many years of concerted research, the ubiquitin-proteasome system has now been extensively studied making it possible to design drugs that target specific events during the protein degradation pathways (Table 3). Due to the involvement of this system in growth related cellular activities, new drugs based on it are under development to target cancer therapy [134]. The first drug in the class that functions by inhibiting the proteasome is bortezomib, a boronic acid dipeptide that went through clinical trials with promising results (Table 3). Bortezomib, a potent, selective, and reversible inhibitor of the proteasome provides prospects for the treatment of relapsed multiple myeloma that is refractory to conventional chemotherapy [135–137]. In 2008, bortezomib (trading as Velcade®) obtained accelerated approval by the United States Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma by injection [138,139]. Since then improvements are being investigated. MLN4924 is the second compound in clinical trials that targets the NEDD8 system (Table 3).

The multi-step enzymatic pathway involved in conjugating the ubiquitin tag provides opportunities for finding “druggable targets” to develop treatment for cancer and other diseases. In this process specificity for substrates is determined mainly at the E3 ligase level and in the case of Ubls, at both the E2 and E3 level. E3 ligases belong to three major classes namely; N-end rule E3s, E3s containing the HECT (Homology to E6AP C-Terminus) domain, and E3s with the RING (Really Interesting New Gene) finger. The potential for E3 ligases as targets for cancer therapy is discussed extensively in a review by [140]. Recently, an inhibitor of Mdm2 known as nutlin entered preclinical studies and is being considered for use together with Velcade® for the treatment of multiple myeloma [141]. Mdm2 is an E3 ligase of the RING-finger type and functions in normal cells by negatively controlling the pro-apoptotic tumor suppressor p53. Mdm2 promotes the ubiquitination of p53 thus targeting it for degradation by the proteasome system.

The Ubls discussed in this review provide new opportunities for drug design as they target specific substrates and biological processes such as cell-cycle regulation, proliferation, apoptosis and DNA repair. SUMO in particular stands out as an attractive target for drug discovery as it requires specific enzymes for conjugation and is implicated in many biological processes. Its role in carcinogenesis and neurodegenerative diseases is well documented [142]. Ubc9, the only E2 enzyme for SUMOylation, has already been proposed as a target for cancer therapy since it is over-expressed in some tumors such as ovarian carcinoma, melanoma and lung adenocarcinoma [143]. Arsenic trioxide has been found to increase the ubiquitination and subsequent degradation of promyelocytic leukemia (PML) by promoting its SUMOylation by SUMO-1 and -2 [144]. It is now regarded to have significant efficacy in treatment of relapsed patients with acute promyelocytic leukemia (APL) [145].
Table 3. Drugs that target the Ubiquitin-proteasome system and Ubls.

| Drug                        | Mode of Action                                                                 | Target                      | Disease                  | State of Development          | Reference     |
|-----------------------------|-------------------------------------------------------------------------------|-----------------------------|--------------------------|-------------------------------|---------------|
| Bortezomib/ Velcade®        | Selective proteasome inhibitor                                                | Proteasome                  | Multiple myeloma         | In clinical use               | [135–137]     |
| Nutlin                      | Mdm2 inhibitor                                                                 | Mdm2                        | Multiple myeloma         | Preclinical                   | [141]         |
| Multiple approaches to target SUMO pathway | Inhibition of the active site Inhibiting association with E1 Blocking association with target protein | The E2 enzyme in the SUMO pathway UBC9 | Cancer                  | Experimental phases          | [146]         |
| Arsenic trioxide            | Targets SUMOylation                                                            | Degradation of PML–RAR-α    | Leukemia                 | In use clinically             | [146]         |
| All-trans retinoic acid     | See above                                                                      | See above                   | See above                | See above                     | [146]         |
| MLN-4924                    | Inhibits NEDD8 E1-activating enzyme (NAE)                                      | NEDD8 activating enzyme (NAE)| Cancer, Multiple myeloma and Hodgkin’s lymphoma | Phase II clinical trials     | [147] [148]  |
| HBX 41108                   | Inhibits USP7 deubiquitinating activity                                        | Ubiquitin-specific proteases (USP) | Cancer                  | Phase I                       | [149]         |
| JNJ26854165                 | Inhibitor                                                                      | E3-Hdm2                     | Multiple myeloma and solid tumors | Phase I                      | [148]         |
| GDC-0152                    | Inhibitor                                                                      | E3-IAP                      | Metastatic malignancies  | Phase I                       | [148]         |
| LCL161                      | Inhibitor                                                                      | E3-IAP                      | Solid tumors             | Phase I                       | [148]         |
| AT-406                      | Inhibitor                                                                      | E3-IAP                      | Solid tumors and lymphoma| Phase I                       | [148]         |
| AEG 35156                   | Inhibitor                                                                      | E3-IAP                      | AML and liver cancer     | Phase II                      | [148]         |
| AEG 40826                   | Inhibitor                                                                      | E3-IAP                      | Lymphoid tumors          | Phase I                       | [148]         |
| TL 32711                    | Inhibitor                                                                      | E3-IAP                      | Solid tumors and lymphoma| Phase I                       | [148]         |
| YM155                       | Inhibitor                                                                      | E3-IAP                      | Lung cancer              | Phase II                      | [148]         |

Acknowledgments

Our research is supported by the National Research Foundation.
References

1. Kerscher, O.; Felberbaum, R.; Hochstrasser, M. Modification of proteins by ubiquitin and ubiquitin-like proteins. *Annu. Rev. Cell Dev. Biol.* **2006**, *22*, 159–180.

2. Hershko, A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. *Cell Death Differ.* **2005**, *12*, 1191–1197.

3. Sadeh, R.; Breitschopf, K.; Bercovich, B.; Zoabi, M.; Kravtsova-Ivantsiv, Y.; Kornitzer, D.; Schwartz, A.; Ciechanover, A. The N-terminal domain of MyoD is necessary and sufficient for its nuclear localization-dependent degradation by the ubiquitin system. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 15690–15695.

4. Ciechanover, A.; Ben-Saadon, R. N-terminal ubiquitination: More protein substrates join in. *Trends Cell Biol.* **2004**, *14*, 103–106.

5. Fajerman, I.; Schwartz, A.L.; Ciechanover, A. Degradation of the Id2 developmental regulator: Targeting via N-terminal ubiquitination. *Biochem. Biophys. Res. Commun.* **2004**, *314*, 505–512.

6. Hershko, A.; Ciechanover, A. The ubiquitin system. *Annu. Rev. Biochem.* **1998**, *67*, 425–479.

7. Jentsch, S.; Pyrowolakis, G. Ubiquitin and its kin: How close are the family ties? *Trends Cell Biol.* **2000**, *10*, 335–341.

8. Herrmann, J.; Lerman, L.O.; Lerman, A. Ubiquitin and ubiquitin-like proteins in protein regulation. *Circ. Res.* **2007**, *100*, 1276–1291.

9. Bohren, K.M.; Nadkarni, V.; Song, J.H.; Gabbay, K.H.; Overbach, D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. *J. Biol. Chem.* **2004**, *279*, 27233–27238.

10. Odagiri, S.; Tanji, K.; Mori, F.; Kakita, A.; Takahashi, H.; Kamitani, T.; Wakabayashi, K. Immunohistochemical analysis of Marinesco bodies, using antibodies against proteins implicated in the ubiquitin-proteasome system, autophagy and aggresome formation. *Neuropathology* **2012**, *32*, 261–266.

11. Zhao, C.; Denison, C.; Huibregtse, J.M.; Gygi, S.; Krug, R.M. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 10200–10205.

12. French, S.W.; Bardag-Gorce, F.; French, B.A.; Li, J.; Oliva, J. The role of innate immunity in the pathogenesis of preneoplasia in drug-induced chronic hepatitis based on a mouse model. *Exp Mol Pathol* **2011**, *91*, 653–659.

13. McNally, T.; Huang, Q.; Janis, R.S.; Lui, Z.; Olejniczak, E.T.; Reilly, R.M. Structural analysis of UBL5, a novel ubiquitin-like modifier. *Protein Sci.* **2003**, *12*, 1562–1566.

14. Allende-Vega, N.; Dayal, S.; Agarwala, U.; Sparks, A.; Bourdon, J.C.; Saville, M.K. p53 is activated in response to disruption of the pre-mRNA splicing machinery. *Oncogene* **2012**, doi:10.1038/onc.2012.38.

15. Kas, K.; Michiels, L.; Merregaert., J. Genomic structure and expression of the human fau gene: Encoding the ribosomal protein S30 fused to a ubiquitin-like protein. *Biochem. Biophys. Res. Commun.* **1992**, *187*, 927–933.

16. Geng, J.; Klionsky, D.J. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. *EMBO Rep.* **2008**, *9*, 859–864.
17. Sasakawa, H.; Sakata, E.; Yamaguchi, Y.; Komatsu, M.; Tatsumi, K.; Kominami, E.; Tanaka, K.; Kato, K. Solution structure and dynamics of Ufm1, a ubiquitin-fold modifier 1. *Biochem. Biophys. Res. Commun.* **2006**, *343*, 21–26.

18. Mather, A.; Rakghotho, M.; Ntwasa, M. SNAMA, a novel protein with a DWNN domain and a RING finger-like motif: A possible role in apoptosis. *Biochim. Biophys. Acta* **2005**, *1727*, 169–176.

19. Schlieker, C.D.; van der Veen, A.G.; Damon, J.R.; Spooner, E.; Ploegh, H.L. A functional proteomics approach links the ubiquitin-related modifier Urm1 to a tRNA modification pathway. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 18255–18260.

20. Matunis, M.J.; Coutavas, E.; Blobel, G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein ranGAP1 between the cytosol and the nuclear pore complex. *J. Cell Biol.* **1996**, *135*, 1457–1470.

21. Jürgen Dohmen, R. SUMO protein modification. *Biochim. Biophys. Acta (BBA)-Mol. Cell Res.* **2004**, *1695*, 113–131.

22. Bayer, P.; Arndt, A.; Metzger, S.; Mahajan, R.; Melchior, F.; Jaenicke, R.; Becker, J. Structure determination of the small ubiquitin-related modifier SUMO-1. *J. Mol. Biol.* **1998**, *280*, 275–286.

23. Meulmeester, E.; Melchior, F. Cell biology: SUMO. *Nature* **2008**, *452*, 709–711.

24. Johnson, E.S. Protein modification by SUMO. *Annu. Rev. Biochem.* **2004**, *73*, 355–382.

25. Su, H.-L.; Li, S.S.L. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. *Gene* **2002**, *296*, 65–73.

26. Hay, R.T. SUMO-specific proteases: A twist in the tail. *Trends Cell Biol.* **2007**, *17*, 370–376.

27. Tatham, M.H.; Jaffray, E.; Vaughan, O.A.; Desterro, J.M.P.; Botting, C.H.; Naismith, J.H.; Hay, R.T. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and ubc9. *J. Biol. Chem.* **2001**, *276*, 35368–35374.

28. Rodriguez, M.S.; Dargemont, C.; Hay, R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. *J. Biol. Chem.* **2001**, *276*, 12654–12659.

29. Castillo-Lluva, S.; Tatham, M.H.; Jones, R.C.; Jaffray, E.G.; Edmondson, R.D.; Hay, R.T.; Malliri, A. SUMOylation of the GTPase Rac1 is required for optimal cell migration. *Nat. Cell Biol.* **2010**, *12*, 1078–1085.

30. Marx, J. SUMO wrestles its way to prominence in the cell. *Science* **2005**, *307*, 836–839.

31. Hay, R.T.; Vuillard, L.; Desterro, J.M.P.; Rodriguez, M.S. Control of NF–κB transcriptional activation by signal induced proteolysis of IκBα. *Phil. Trans. R. Soc. Lond. B* **1999**, *354*, 1601–1609.

32. Mabb, A.; Miyamoto, S. SUMO and NF–κB ties. *Cell Mol. Life Sci.* **2007**, *64*, 1979–1996.

33. Kirsh, O.; Seeler, J.-S.; Pichler, A.; Gast, A.; Muller, S.; Miska, E.; Mathieu, M.; Harel-Bellan, A.; Kouzarides, T.; Melchior, F.; et al. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. *EMBO J.* **2002**, *21*, 2682–2691.

34. Yamamoto, H.; Ihara, M.; Matsuura, Y.; Kikuchi, A. Sumoylation is involved in [beta]-catenin-dependent activation of Tcf-4. *EMBO J.* **2003**, *22*, 2047–2059.

35. Ihara, M.; Yamamoto, H.; Kikuchi, A. SUMO-1 modification of PIASy, an E3 ligase, is necessary for PIASy-dependent activation of Tcf-4. *Mol. Cell Biol.* **2005**, *25*, 3506–3518.
36. Goodson, M.L.; Hong, Y.; Rogers, R.; Matunis, M.J.; Park-Sarge, O.-K.; Sarge, K.D. SUMO-1 modification regulates the DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor. *J. Biol. Chem.* 2001, 276, 18513–18518.

37. Stehmeier, P.; Muller, S. Regulation of p53 family members by the ubiquitin-like SUMO system. *DNA Repair.* 2009, 8, 491–498.

38. Rodriguez, M.S.; Desterro, J.M.P.; Lain, S.; Midgley, C.A.; Lane, D.P.; Hay, R.T. SUMO-1 modification activates the transcriptional response of p53. *EMBO J.* 1999, 18, 6455–6461.

39. Hoege, C.; Pfander, B.; Moldovan, G.-L.; Pyrowolakis, G.; Jentsch, S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. *Nature* 2002, 419, 135–141.

40. Bergink, S.; Jentsch, S. Principles of ubiquitin and SUMO modifications in DNA repair. *Nature* 2009, 458, 461–467.

41. Owerbach, D.; McKay, E.M.; Yeh, E.T.H.; Gabby, K.H.; Bohren, K.M. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. *Biochem. Biophys. Res. Commun.* 2005, 337, 517–520.

42. Kumar, S.; Yoshida, Y.; Noda, M. Cloning of a cDNA which encodes a novel ubiquitin-like protein. *Biochem. Biophys. Res. Commun.* 1993, 195, 393–399.

43. Ohki, Y.; Funatsu, N.; Konishi, N.; Chiba, T. The mechanism of poly-NEDD8 chain formation in vitro. *Biochem. Biophys. Res. Commun.* 2009, 381, 443–447.

44. Liakopoulos, D.; Doenges, G.; Matuschewski, K.; Jentsch, S. A novel protein modification pathway related to the ubiquitin system. *EMBO J.* 1998, 17, 2208–2214.

45. Hori, T.; Osaka, F.; Chiba, T.; Miyamoto, C.; Okabayashi, K.; Shimbara, N.; Kato, S.; Tanaka, K. Covalent modification of all members of human cullin family proteins by NEDD8. *Oncogene* 1999, 18, 6829–6834.

46. Kawakami, T.; Chiba, T.; Suzuki, T.; Iwai, K.; Yamanaka, K.; Minato, N.; Suzuki, H.; Shimbara, N.; Hidaka, Y.; Osaka, F.; et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. *EMBO J.* 2001, 20, 4003–4012.

47. Watson, I.R.; Irwin, M.S.; Ohh, M. NEDD8 pathways in cancer, sine quibus non. *Cancer Cell* 2011, 19, 168–176.

48. Deshaies, R.J.; Emberley, E.D.; Saha, A. Control of cullin-ring ubiquitin ligase activity by Nedd8. *Subcell. Biochem.* 2010, 54, 41–56.

49. Sarikas, A.; Hartmann, T.; Pan, Z.-Q. The cullin protein family. *Genome Biol.* 2011, 12, 220.

50. Liu, L.; Lee, S.; Zhang, J.; Peters, S.B.; Hannah, J.; Zhang, Y.; Yin, Y.; Koff, A.; Ma, L.; Zhou, P. CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. *Mol. Cell* 2009, 34, 451–460.

51. Du, J.; Zhang, J.; Su, Y.; Liu, M.; Ospina, J.K.; Yang, S.; Zhu, A.J. In vivo RNAi screen reveals Neddylation genes as novel regulators of Hedgehog signaling. *PLoS One* 2011, 6, e24168.

52. Gao, F.; Cheng, J.; Shi, T.; Yeh, E.T.H. Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFκB-dependent transcription. *Nat. Cell Biol.* 2006, 8, 1171–1177.
53. Stickle, N.H.; Chung, J.; Klco, J.M.; Hill, R.P.; Kaelin, W.G., Jr.; Ohh, M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. *Mol. Cell Biol.* **2004**, *24*, 3251–3261.

54. Xirodimas, D.P.; Sundqvist, A.; Nakamura, A.; Shen, L.; Botting, C.; Hay, R.T. Ribosomal proteins are targets for the NEDD8 pathway. *EMBO Rep.* **2008**, *9*, 280–286.

55. Shamay, M.; Greenway, M.; Liao, G.; Ambinder, R.F.; Hayward, D. De novo DNA methyltransferase DNMT3b interacts with NEDD8-modified proteins. *J. Biol. Chem.* **2010**, *285*, 36377–36386.

56. Broemer, M.; Tenev, T.; Rigbolt, K.T.G.; Hempel, S.; Blagoev, B.; Silke, J.; Ditzel, M.; Meier, P. Systematic *in vivo* RNAi analysis identifies IAPs as NEDD8-E3 ligases. *Mol. Cell* **2010**, *40*, 810–822.

57. Fan, W.; Cai, W.; Parimoo, S.; Lennon, G.G.; Weissman, S.M. Identification of seven new human MHC class I region genes around the HLA-F locus. *Immunogenetics* **1996**, *44*, 97–103.

58. Liu, Y.-C.; Pan, J.; Zhang, C.; Fan, W.; Collinge, M.; Bender, J.R.; Weissman, S.M. A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 4313–4318.

59. Lee, C.G.; Ren, J.; Cheong, I.S.; Ban, K.H.; Ooi, I.L.; Tan, S.Y.; Kan, A.; Nuchprayoon, I.; Jin, R.; Lee, K.-H.; *et al.* Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers *Oncogene* **2003**, *22*, 2592–2603.

60. Aichem, A.; Pelzer, C.; Lukasiak, S.; Kalveram, B.; Sheppard, P.W.; Rani, N.; Schmidtke, G.; Groettrup, M. USE1 is a bifunctional conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. *Nat. Commun.* **2010**, *1*, doi:10.1038/ncomms1012.

61. Chiu, Y.H.; Sun, Q.; Chen, Z.J. E1-L2 activates both ubiquitin and FAT10. *Mol. Cell Biol.* **2007**, *27*, 1014–1023.

62. Lukasiak, S.; Schiller, C.; Oehlshlaeger, P.; Schmidtke, G.; Krause, P.; Legler, D.F.; Autschbach, F.; Schirmacher, P.; Breuhahn, K.; Groettrup, M. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. *Oncogene* **2008**, *27*, 6068–6074.

63. Canaan, A.; Yu, X.; Booth, C.J.; Lian, J.; Lazar, I.; Gamfi, S.L.; Castille, K.; Kohya, N.; Nakayama, Y.; Liu, Y.-C.; *et al.* FAT10/Diubiquitin-like protein-deficient mice exhibit minimal phenotypic differences. *Mol. Cell Biol.* **2006**, *26*, 5180–5189.

64. Gong, P.; Canaan, A.; Wang, B.; Leventhal, J.; Snyder, A.; Nair, V.; Cohen, C.D.; Kretzler, M.; D’Agati, V.; Weissman, S.; *et al.* The ubiquitin-like protein FAT10 mediates NF–κB activation. *J. Am. Soc. Nephrol.* **2010**, *21*, 316–326.

65. Li, T.; Santockyte, R.; Yu, S.; Shen, R.-F.; Tekle, E.; Lee, C.G.L.; Yang, D.C.H.; Chock, P.B. FAT10 modifies p53 and upregulates its transcriptional activity. *Arch. Biochem. Biophys.* **2011**, *509*, 164–169.

66. Ren, J.; Wang, Y.; Gao, Y.; Mehta, S.B.K.; Lee, C.G.L. FAT10 mediates the effect of TNF-α in inducing chromosomal instability. *J. Cell Sci.* **2011**, *124*, 3665–3675.

67. Raasi, S.; Schmidtke, G.; Groettrup, M. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. *J. Biol. Chem.* **2001**, *276*, 35334–35343.

68. Buchsbaum, S.; Bercovich, B.; Ciechanover, A. FAT10 is a proteasomal degradation signal that is itself regulated by ubiquitination. *Mol. Biol. Cell* **2012**, *23*, 225–232.
69. Zhang, D.W.; Jeang, K.T.; Lee, C.G.L. p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. *Oncogene* **2006**, 25, 2318–2327.

70. Doyle, S.E.; Vaidya, S.A.; O’Connell, R.; Dadgostar, H.; Dempsey, P.W.; Wu, T.-T.; Rao, G.; Sun, R.; Haberland, M.E.; Modlin, R.L.; *et al.* IRF3 mediates a TLR3/TLR4-specific antiviral gene program. *Immunity* **2002**, 17, 251–263.

71. Martensen, P.M. Small ISGs coming forward. *J. Interferon Cytokine Res.* **2004**, 24, 1–19.

72. Reich, N.; Evans, B.; Levy, D.; Fahey, D.; Knight, E., Jr.; Darnell, J.E., Jr. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element (promoter/transcription regulation). *Proc. Natl. Acad. Sci. USA* **1987**, 84, 6394–6398.

73. Hummer, B.T.; Li, X.L.; Hassel, B.A. Role for p53 in gene induction by double-stranded RNA. *J. Virol.* **2001**, 75, 7774–7777.

74. Jeon, Y.J.; Yoo, H.M.; Chung, C.H. ISG15 and immune diseases. *Biochim. Biophys. Acta Mol. Basis Dis.* **2010**, 1802, 485–496.

75. Zou, W.; Zhang, D.-E. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. *J. Biol. Chem.* **2006**, 281, 3989–3994.

76. Wong, J.J.Y.; Pung, Y.F.; Sze, N.S.-K.; Chin, K.-C. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. *Proc. Natl. Acad. Sci. USA* **2006**, 103, 10735–10740.

77. Van der Veen, A.G.; Ploegh, H.L. Ubiquitin-like proteins. *Annu. Rev. Biochem.* **2012**, 81, 323–357.

78. Skaug, B.; Chen, Z.J. Emerging role of ISG15 in antiviral immunity. *Cell* **2010**, 143, 187–190.

79. Durfee, L.A.; Lyon, N.; Seo, K.; Huibregtse, J.M. The ISG15 conjugation system broadly targets newly synthesized proteins: Implications for the antiviral function of ISG15. *Mol. Cell* **2010**, 38, 722–732.

80. Nisole, S.; Stoye, J.P.; Saïb, A. Trim family proteins: Retroviral restriction and antiviral defense. *Nat. Rev. Microbiol.* **2005**, 3, 799–808.

81. Nakasato, N.; Ikeda, K.; Urano, T.; Horie-Inoue, K.; Takeda, S.; Inoue, S. A ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with ISG15. *Biochem. Biophys. Res. Commun.* **2006**, 351, 540–546.

82. Lenschow, D.J.; Giannakopoulos, N.V.; Gunn, L.J.; Johnston, C.; O’Guin, A.K.; Schmidt, R.E.; Levine, B.; Virgin, H.W., IV. Identification of interferon-stimulated gene 15 as an antiviral molecule during sindbis virus infection *in vivo*. *J. Virol.* **2005**, 79, 13974–13983.

83. Lenschow, D.J.; Lai, C.; Frias-Staheli, N.; Giannakopoulos, N.V.; Lutz, A.; Wolff, T.; Osiak, A.; Levine, B.; Schmidt, R.E.; Garcia-Sastre, A.; *et al.* IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. *Proc. Natl. Acad. Sci. USA* **2007**, 104, 1371–1376.

84. Okumura, A.; Lu, G.; Pitha-Rowe, I.; Pitha, P.M. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. *Proc. Natl. Acad. Sci. USA* **2006**, 103, 1440–1445.

85. Okumura, A.; Pitha, P.M.; Harty, R.N. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. *Proc. Natl. Acad. Sci. USA* **2008**, 105, 3974–3979.
86. Yuan, W.; Krug, R.M. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. *EMBO J.* **2001**, *20*, 362–371.

87. Tang, Y.; Zhong, G.; Zhu, L.; Liu, X.; Shan, Y.; Feng, H.; Bu, Z.; Chen, H.; Wang, C. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. *J. Immunol.* **2010**, *184*, 5777–5790.

88. Akutsu, M.; Ye, Y.; Virdee, S.; Chin, J.W.; Komander, D. Molecular basis for ubiquitin and ISG15 cross-reactivity in viral ovarian tumor domains. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 2228–2233.

89. Malakhova, O.A.; Yan, M.; Malakhov, M.P.; Yuan, Y.; Ritchie, K.J.; Kim, K.I.; Peterson, L.F.; Shuai, K.; Zhang, D.-E. Protein ISGylation modulates the JAK-STAT signaling pathway. *Genes Dev.* **2003**, *17*, 455–460.

90. Jeon, Y.J.; Choi, J.S.; Lee, J.Y.; Yu, K.R.; Kim, S.; Ka, S.H.; Oh, K.H.; Kim, K.I.; Zhang, D.-E.; Bang, O.S.; *et al.* ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway. *EMBO Rep.* **2009**, *10*, 374–380.

91. He, C.; Klionsky, D.J. Regulation mechanisms and signaling pathways of autophagy. *Annu. Rev. Genet.* **2009**, *3*, 67–93.

92. Hanada, T.; Ohsumi, Y. Structure-function relationship of Atg12, a ubiquitin-like modifier essential for autophagy. *Autophagy* **2005**, *1*, 110–118.

93. Ichimura, Y.; Kirisako, T.; Takao, T.; Satomi, Y.; Shimonishi, Y.; Ishihara, N.; Mizushima, N.; Tanida, I.; Kominami, E.; Ohsumi, M.; *et al.* A ubiquitin-like system mediates protein lipidation. *Nature* **2000**, *408*, 488–492.

94. Kirisakoa, T.; Ichimura, Y.; Okadac, H.; Kabeyaa, Y.; Mizushimaa, N.; Yoshimoria, T.; Ohsumic, M.; Takaoe, T.; Nodaa, T.; Ohsumia, Y. The reversible modification regulates the membrane-binding state of APG8/AUT7 essential for autophagy and the cytoplasm to vacuole targeting pathway. *J. Cell Biol.* **2000**, *151*, 263–275.

95. Tanida, I.; Tanida-Miyake, E.; and, T.U.; Kominami, E. The human homolog of saccharomyces cerevisiae Apg7p is a protein-activating enzyme for multiple substrates including human Apg12p, GATE-16, GABARAP, and MAP-LC3. *J. Biol. Chem.* **2001**, *276*, 1701–1706.

96. Shintani, T.; Mizushima, N.; Ogawa, Y.; Matsuura, A.; Noda, T.; Ohsum, Y. Apg10p, a novel protein-conjugating enzyme essential for autophagy in yeast. *EMBO J.* **1999**, *18*, 5234–5241.

97. Mizushima, N.; Noda, T.; Ohsumi, Y. Apg16p is required for the function of the Apg12p-Apg5p conjugate in the yeast autophagy pathway. *EMBO J.* **1999**, *18*, 3888–3896.

98. Radoshevich, L.; Murrow, L.; Chen, N.; Fernandez, E.; Roy, S.; Fung, C.; Debnath, J. ATG12 conjugation to ATG3 regulates mitochondrial homeostasis and cell death. *Cell* **2010**, *142*, 590–600.

99. Furukawa, K.; Mizushima, N.; Noda, T.; Ohsumi, Y. A protein conjugation system in yeast with homology to biosynthetic enzyme reaction of prokaryotes. *J. Biol. Chem.* **2000**, *275*, 7462–7465.

100. Singh, S.; Tonelli, M.; Tyler, R.C.; Bahrami, A.; Lee, M.S.; Markley, J.L. Three-dimensional structure of the AAH26994.1 protein from *Mus musculus*, a putative eukaryotic Urm1. *Protein Sci.* **2005**, *14*, 2095–2102.
101. Komatsu, M.; Chiba, T.; Tatsumi, K.; Iemura, S.; Tanida, I.; Okazaki, N.; Ueno, T.; Kominami, E.; Natsume, T.; Tanaka, K. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. *EMBO J.* 2004, 23, 1977–1986.

102. Tatsumi, K.; Sou, Y.-S.; Tada, N.; Nakamura, E.; Iemura, S.-I.; Natsume, T.; Kang, S.H.; Chung, C.H.; Kasahara, M.; Kominami, E.; *et al.* A novel type of E3 ligase for the Ufm1 conjugation system. *J. Biol. Chem.* 2010, 285, 5417–5427.

103. Tatsumi, K.; Yamamoto-Mukai, H.; Shimizu, R.; Waguri, S.; Sou, Y.S.; Sakamoto, A.; Taya, C.; Shitara, H.; Harai, T.; Chung, C.H.; *et al.* The Ufm1-activating enzyme Uba5 is indispensable for erythroid differentiation in mice. *Nat. Commun.* 2011, 2, 181.

104. Pugh, D.; Eiso, A.B.; Faro, A.; Lutya, P.; Hoffmann, E.; Rees, D.J. DWNN, a novel ubiquitin-like domain, implicates RBBP6 in mRNA processing and ubiquitin-like pathways. *BMC Struct. Biol.* 2006, 6, doi:10.1186/1472-6807-6-1.

105. Ntwasa, M. The retinoblastoma binding protein 6 is a potential target for therapeutic drugs. *Biotechnol. Mol. Biol. Rev.* 2008, 3, 24–31.

106. Li, L.; Deng, B.; Xing, G.; Teng, Y.; Tian, C.; Cheng, X.; Yin, X.; Yang, J.; Gao, X.; Zhu, Y., *et al.* PACT is a negative regulator of p53 and essential for cell growth and embryonic development. *Proc. Natl. Acad. Sci. USA* 2007, 104, 7951–7956.

107. Jones, S.N.; Roe, A.E.; Donehower, L.A.; Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. *Nature* 1995, 378, 206–208.

108. Shimizu, N.; Minoshima, S.; Asakawa, S. Cloning of Parkin gene and its function. *No To Shinkei* 1999, 51, 487–491.

109. Bronner, C.; Achour, M.; Arima, Y.; Chataigneau, T.; Saya, H.; Schini-Kerth, V.B. The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future? *Pharmacol. Ther.* 2007, 115, 419–434.

110. Masutani, C.; Sugasawa, K.; Yanagisawa, J.; Sonoyama, T.; Ui, M.; Enomoto, T.; Takio, K.; Tanaka, K.; van der Spek, P.J.; Bootsma, D.; *et al.* Purification and cloning of a nucleotide excision repair complex involving the xeroderma pigmentosum group C protein and a human homologue of yeast RAD23. *EMBO J.* 1994, 13, 1831–1843.

111. Gamerdinger, M.; Hajieva, P.; Kaya, A.M.; Wolfrum, U.; Hartl, F.U.; Behl, C. Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. *EMBO J.* 2009, 28, 889–901.

112. Leznicki, P.; Clancy, A.; Schwappach, B.; High, S. Bat3 promotes the membrane integration of tail-anchored proteins. *J. Cell Sci.* 2010, 123, 2170–2178.

113. Sirkis, R.; Gerst, J.E.; Fass, D. Ddi1, a eukaryotic protein with the retroviral protease fold. *J. Mol. Biol.* 2006, 364, 376–387.

114. Hartmann, R.; Olsen, H.S.; Widder, S.; Jørgensen, R.; Justesen, J. p59OASL, a 2′-5′ oligoadenylate synthetase like protein: A novel human gene related to the 2′-5′ oligoadenylate synthetase family. *Nucleic Acids Res.* 1998, 26, 4121–4127.

115. Kokame, K.; Agarwala, K.L.; Kato, H.; Miyata, T. Herp, a new ubiquitin-like membrane protein induced by endoplasmic reticulum stress. *J. Biol. Chem.* 2000, 275, 32846–32853.

116. Ozaki, T.; Hishiki, T.; Toyama, Y.; Yuasa, S.; Nakagawara, A.; Sakiyama, S. Identification of a new cellular protein that can interact specifically with DAN. *DNA Cell Biol.* 1997, 16, 985–991.
Saia, X.; Kokame, K.; Shiraishia, H.; Kawamuraa, Y.; Miyata, T.; Yanagisawa, K.; Komano, H. The ubiquitin-like domain of herp is involved in Herp degradation, but not necessary for its enhancement of amyloid β-protein generation. FEBS Lett. 2003, 553, 151–156.

Slodzinski, H.; Moran, L.B.; Michael, G.J.; Wang, B.; Novoselov, S.; Cheetham, M.E.; Pearce, R.K.; Graeber, M.B. Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies. Clin. Neuropathol. 2009, 28, 333–343.

Chan, S.L.; Fu, W.; Zhang, P.; Cheng, A.; Lee, J.; Kokame, K.; Mattson, M.P. Herp stabilizes neuronal Ca\textsuperscript{2+} homeostasis and mitochondrial function during endoplasmic reticulum stress. J. Biol. Chem. 2004, 279, 28733–28743.

Hori, O.; Ichinoda, F.; Yamaguchi, A.; Tamatani, T.; Taniguchi, M.; Koyama, Y.; Katayama, T.; Tohyama, M.; Stern, D.M.; Ozawa, K.; et al. Role of Herp in the endoplasmic reticulum stress response. Genes Cells 2004, 9, 457–469.

Kitada, T.; Asakawa, S.; Minoshima, S.; Mizuno, Y.; Shimizu, N. Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm. Genome 2000, 11, 417–421.

Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392, 605–608.

Shimura, H.; Hattori, N.; Kubo, S.-I.; Mizuno, Y.; Asakawa, S.; Minoshima, S.; Shimizu, N.; Iwai, K.; Chiba, T.; Tanaka, K.; et al. Familial parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25, 302–305.

Cookson, M.R. Parkin’s substrates and the pathways leading to neuronal damage. NeuroMol. Med. 2003, 3, 1–13.

Bae, Y.-J.; Kang, S.-J.; Park, K.S. Drosophila melanogaster Parkin ubiquitinates peanut and septin1 as an E3 ubiquitin–protein ligase. Insect Biochem. Mol. Biol. 2007, 37, 430–439.

Witte, M.M.; Scott, R.E. The proliferation potential protein-related (P2P-R) gene with domains encoding heterogeneous nuclear ribonucleoprotein association and Rb1 binding shows repressed expression during terminal differentiation. Proc. Natl. Acad. Sci. USA 1997, 94, 1212–1217.

Simons, A.; Melamed-Bessudo, C.; Wolkowicz, R.; Sperling, J.; Sperling, R.; Eisenbach, L.; Rotter, V. PACT: Cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene 1997, 14, 145–155.

Scott, R.E.; Giannakouros, T.; Gao, S.; Peidis, P. Functional potential of P2P-R: A role in the cell cycle and cell differentiation related to its interactions with proteins that bind to matrix associated regions of DNA? J. Cell Biochem. 2003, 90, 6–12.

Conklina, D.; Holdermana, S.; Whitmoreb, T.E.; Maurerb, M.; Feldhaus, A.L. Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene 2000, 249, 91–98.

Ko, H.S.; Uehara, T.; Nomura, Y. Role of ubiquilin associated with protein-disulfide isomerase in the endoplasmic reticulum in stress-induced apoptotic cell death. J. Biol. Chem. 2002, 277, 35386–35392.
131. Hoeller, D.; Hecker, C.-M.; Dikic, I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006, 6, 776-788.

132. Liu, M.; Hummer, T.; Li, X.; Hassel, B.A. Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon. J. Interferon Cytokine Res. 2004, 24, 647–654.

133. Ohwada, S.; Kobayashi, I.; Maemura, M.; Satoh, Y.; Ogawa, T.; Iino, Y.; Morishita, Y. Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts. Cancer Lett. 1996, 110, 149–154.

134. Yang, Y.; Kitagaki, J.; Wang, H.; Hou, D.-X.; Perantoni, A.O. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 2009, 100, 24–28.

135. Richardson, P.G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; et al. A Phase 2 study of Bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609–2617.

136. Jagannath, S.; Barlogie, B.; Berenson, J.; Siegel, D.; Irwin, D.; Richardson, P.G.; Niesvizky, R.; Alexanian, R.; Limentani, S.A.; Alsina, M.; et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 2004, 127, 165–172.

137. Orlowski, R.Z.; Nagler, A.; Sonneveld, P.; Bladé, J.; Hajek, R.; Spencer, A.; San Miguel, J.; Robak, T.; Dmoszynska, A.; Horvath, N.; et al. Randomized Phase III study of Pegylated liposomal Doxorubicin plus Bortezomib compared with Bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J. Clin. Oncol. 2007, 25, 3892–3901.

138. National Cancer Institute. Fda approval for Bortezomib. Available online: http://www.cancer.gov/cancertopics/druginfo/fda-bortezomib (accessed on 1 June 2012).

139. Kane, R.C.; Bross, P.F.; Farrell, A.T.; Pazdur, R. Velcade®: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8, 508–513.

140. Sun, Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Ther. 2003, 2, 623–629.

141. Saha, M.N.; Jiang, H.; Jayakar, J.; Reece, D.; Branch, D.R.; Chang, H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol. Ther. 2010, 9, 936–944.

142. Bettermann, K.; Benesch, M.; Weis, S.; Haybaeck, J. SUMOylation in carcinogenesis. Cancer Lett. 2012, 316, 113–125.

143. Mo, Y.-Y.; Moschos, S.J. Targeting Ubc9 for cancer therapy. Expert Opin. Ther. Tar 2005, 9, 1203–1216.

144. Weisshaar, S.R.; Keusekotten, K.; Krause, A.; Horst, C.; Springer, H.M.; Göttche, K.; Dohmen, R.J.; Praefcke, G.J.K. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBS Lett. 2008, 582, 3174–3178.

145. Miller, W.H.; Schipper, H.M.; Lee, J.S.; Singer, J.; Waxman, S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62, 3893–3903.

146. Hoeller, D.; Dikic, I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458, 438–444.
147. Soucy, T.A.; Smith, P.G.; Milhollen, M.A.; Berger, A.J.; Gavin, J.M.; Adhikari, S.; Brownell, J.E.; Burke, K.E.; Cardin, D.P.; Critchley, S.; et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. *Nature* 2009, 458, 732–736.

148. Cohen, P.; Tcherpakov, M. Will the ubiquitin system furnish as many drug targets as protein kinases? *Cell* 2010, 143, 686–693.

149. Colland, F.; Formstecher, E.; Jacq, X.; Reverdy, C.; Planquette, C.; Conrath, S.; Trouplin, V.; Bianchi, J.; Aushev, V.N.; Camonis, J.; et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. *Mol. Cancer Ther.* 2009, 8, 2286–2295.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).